Crovalimab Dosing Regimen for PNH Treatment
Solution Overview
Problem
Current treatments for paroxysmal nocturnal hemoglobinuria (PNH) using anti-C5 antibodies like Eculizumab are ineffective for individuals with specific C5 polymorphisms, leading to poor control of intravascular hemolysis, and there is a need for a dosing regimen that minimizes the formation of Drug-Target-Drug-Complexes (DTDCs) and maintains sustained terminal complement inhibition.
Innovation Solution
A dosing regimen involving an initial intravenous loading dose of 1500 mg of the anti-C5 antibody Crovalimab followed by subcutaneous administration of 340 mg loading doses and subsequent maintenance doses of 1020 mg every 4 weeks, ensuring sustained terminal complement inhibition and reducing DTDC formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-C5 antibody Eculizumab is used to treat PNH, then complement-mediated hemolysis is inhibited, but treatment is ineffective for individuals with specific C5 polymorphisms leading to poor control of intravascular hemolysis
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the anti-C5 antibody to create variants with altered binding characteristics. Specifically, antibodies with mutations in the CDR regions (such as H3 L31F, H3 L35F, H3 L31F/L35F combinations) are designed to maintain or improve binding affinity to C5 across different polymorphic forms, thereby resolving the contradiction between treatment effectiveness and adaptability to genetic variations.
2Reliability
If high doses of anti-C5 antibody are administered to ensure sustained terminal complement inhibition, then complete blockade of the complement pathway is achieved, but formation of Drug-Target-Drug-Complexes (DTDCs) increases
Solution Approach 1:
The patent employs parameter changes by optimizing the antibody dosing regimen and modifying antibody properties to reduce DTDC formation. The optimized regimen uses lower maintenance doses (e.g., 300 mg every 4 weeks) combined with loading doses, and the engineered antibody variants exhibit improved pharmacokinetic properties that minimize complex formation while maintaining effective complement inhibition.
Solution Approach 2:
The patent applies preliminary action through the use of loading doses administered before maintenance doses. The loading doses (e.g., 1000 mg IV on day 1, followed by 300 mg SC on days 2, 8, and 15) establish therapeutic antibody levels rapidly, allowing subsequent maintenance doses to be lower and less frequent, thereby reducing overall DTDC formation while ensuring sustained complement pathway blockade.
3Duration of action of stationary object
If frequent dosing is used to maintain therapeutic antibody levels, then sustained terminal complement inhibition is achieved, but treatment complexity and patient burden increase
Solution Approach 1:
The patent applies preliminary action by administering loading doses at the beginning of treatment to rapidly achieve therapeutic antibody levels. This initial intensive dosing (IV loading dose followed by multiple SC loading doses within the first 2 weeks) establishes sufficient drug concentration to inhibit complement activation, allowing subsequent maintenance doses to be spaced 4 weeks apart, thereby reducing treatment frequency while sustaining therapeutic effect.
Solution Approach 2:
The patent employs dynamics by implementing a time-varying dosing regimen that transitions from frequent loading doses to less frequent maintenance doses. The regimen adapts the dosing frequency and route (IV to SC) over time based on the pharmacokinetic profile and therapeutic requirements, optimizing the balance between sustained complement inhibition and treatment convenience.
4Speed
If intravenous administration is used to ensure rapid therapeutic effect, then complete complement pathway blockade is achieved quickly, but patient convenience and ease of administration decrease
Solution Approach 1:
The patent applies preliminary action by using intravenous administration for the initial loading dose to rapidly achieve therapeutic antibody levels and ensure complete complement pathway blockade. Subsequent maintenance doses are administered subcutaneously, which is more convenient for patients and can be self-administered at home, thereby balancing rapid onset of action with long-term treatment convenience.
Solution Approach 2:
The patent employs segmentation by dividing the treatment regimen into different administration phases with different routes: intravenous loading dose for rapid effect, followed by subcutaneous maintenance doses for convenience. This segmentation allows the treatment to address both the need for rapid therapeutic effect and the need for patient convenience in the long term.
Data Source
AI summary
The present invention relates to a dosage and administration regimen of anti-C5 antibodies, particularly of the anti-C5 antibody Crovalimab, for use in a method of treating or preventing C5-related disease in a subject, including paroxysmal nocturnal hemoglobinuria (PNH). The dosage and treatment regimen of the present invention include the administration of an anti-C5 antibody, preferably of the anti-C5 antibody Crovalimab, with loading doses followed by the administration of (a) maintenance dose(s) of the anti-C5 antibody to the subject, wherein the initial administered loading dose is intravenously given to the subject and the remaining loading and maintenance doses are subcutaneously administered in a lower dosage as the intravenously administered loading dose.